Table 2.

Association between imaging traits and gene expression profiles (from logistic regression analysis). Data are listed in ascending odds ratio (OR) values for each variable. Only associations with confidence intervals (CI) not overlapping with 1 and P <0.05 are shown.

Imaging trait	Genomic variable	OR	95% CI	P
Infiltrative pattern	Boyault_G3 [25]	6.05	1.06-34.38	0.042
	Chiang_Proliferation [22]	6.57	1.30–33.33	0.023
	Hoshida_S1/S2 [12]	7.00	1.22–40.09	0.029
	Minguez_Vascular invasion [9]	7.00	1.22–40.09	0.029
	Woo_Cholangiocarcinoma_like [26]	7.00	1.22–40.09	0.029
	Andersen_KRT19 [27]	9.63	1.64–56.37	0.012
	Coulouarn_TGF-beta [28]	9.63	1.64–56.37	0.012
	Villanueva_KRT19 [6]	11.50	1.93–68.52	0.007
Macrovascular invasion	Cairo_Hepatoblastoma [47]	6.75	1.19–38.41	0.031
	Boyault_G3 [25]	12.73	1.38–117.27	0.025
Size > 5 cm	Villanueva_KRT19 [6]	4.44	1.08–18.36	0.039
	Andersen_KRT19 [27]	5.50	1.32–22.86	0.019
	Coulouarn_TGF-beta [28]	5.50	1.32–22.86	0.019
Mosaic appearance	Boyault_G3 [25]	10.46	1.16–94.48	0.037
Wash-in / no wash-out	Hoshida_S2 [12]	11.25	1.42–89.26	0.022
Enhancement ratio (arterial phase)	Yamashita_EpCAM [48]	0.96	0.93–0.99	0.033
	Cairo_Hepatoblastoma [47]	0.96	0.93–0.99	0.044
Tumour-to-liver contrast ratio (arterial phase)	Yamashita_EpCAM [48]	0.96	0.94–0.99	0.046
	Cairo_Hepatoblastoma [37]	0.95	0.91–0.99	0.023
	Woo_Cholangiocarcinoma_like [26]	0.97	0.95–0.99	0.037
Tumour-to-liver contrast ratio (portal venous phase)	Andersen_KRT19 [27]	0.91	0.85–0.98	0.017
	Boyault_G3 [25]	0.92	0.86–0.98	0.022
	Cairo_Hepatoblastoma [47]	0.92	0.86–0.99	0.031
	Villanueva_KRT19 [6]	0.91	0.84–0.98	0.017
	Coulouarn_TGF-beta [28]	0.90	0.83–0.98	0.014
	Hoshida_S1 [12]	0.93	0.87–0.99	0.03
	Lee_Poor survival [49]	0.93	0.87–0.99	0.03
	Novak_Met [50]	0.93	0.88–0.99	0.043
	Villanueva_KRT19 [6]	0.94	0.89–0.99	0.045
	Woo_Cholangiocarcinoma_like [26]	0.91	0.85–0.99	0.019
	Woo_Recurrence [51]	0.89	0.81–0.97	0.012